IEPA, a novel radiation countermeasure, alleviates acute radiation syndrome in rodents. (PubMed, Int J Radiat Biol) - Nov 15, 2024 - "IEPA (imidazolyl ethanamide pentandioic acid) is an orally bioavailable small molecule pseudopeptide with myeloprotective properties, a good clinical safety profile, and stable chemical characteristics facilitating stockpiling...IEPA treatment is compatible with Neulasta® (Pegfilgrastim; PEG-G-CSF); adequately powered studies are needed to confirm the trend toward improved survival over standard care alone. IEPA is a promising development candidate as a medical countermeasure against the effects of acute radiation syndrome. Further confirmatory studies in small and large animal models should validate the robustness and translatability of preliminary rodent data on IEPA's radiomitigative efficacy."
Journal • Preclinical • Hematological Disorders
|
|
Brian L Fish; Christie M Orschell; Corinna Asang; Dirk Pleimes; Heather A Himburg; Maciej T Czajkowski; Michael Eibl; Nikita Singh; Radoslaw Wesolowski; Srishti Munjal Mehta; Stella Bähr; Tracy Gasperetti
|